AFN-1252: Phase IIa data

An open-label, U.S. and Canadian Phase IIa trial in 103 patients with ABSSSI due to Staphylococcus showed that twice-daily 200 mg oral AFN-1252 for 5-14 days led to an overall cure rate, defined as re...